A Review of THC's Therapeutic Potential and the Challenges That Limit Its Medical Use
THC shows wide-ranging therapeutic potential across multiple conditions, but psychoactive side effects, tolerance development, and dependence risk continue to limit its clinical application.
Quick Facts
What This Study Found
This review covered the pharmacological landscape of THC as of 2007, drawing on clinical trials, animal studies, and anecdotal reports.
The evidence supported THC's therapeutic applications across several areas including pain relief, nausea suppression, appetite stimulation, neuroprotection, and anti-tumor effects. The discovery of the endocannabinoid system (CB1 and CB2 receptors and their natural ligands) had enabled more targeted research into these applications.
However, the review noted persistent barriers: psychoactive effects in patients, adverse reactions reported in human trials, tolerance development with repeated use, and potential dependence. These issues pushed researchers toward alternative strategies, including drugs that modulate the endocannabinoid system indirectly rather than activating cannabinoid receptors directly.
Intriguingly, emerging evidence suggested that whole cannabis extracts sometimes outperformed isolated THC, hinting at synergistic effects between cannabis compounds.
Key Numbers
The review covered applications in pain, nausea, appetite, neuroprotection, and cancer. Whole cannabis extract showed benefits beyond those of isolated THC in some comparisons.
How They Did This
This was a narrative review of the published literature on THC pharmacology, covering cellular and molecular mechanisms, animal model results, and clinical trial data. The author organized findings by therapeutic application and discussed limitations and future directions.
Why This Research Matters
This review captured a pivotal moment in cannabinoid pharmacology when the field was shifting from studying THC in isolation toward understanding the broader endocannabinoid system and whole-plant preparations. The observation that whole extracts sometimes work better than pure THC foreshadowed the "entourage effect" concept.
The Bigger Picture
The tension identified in this review between THC's therapeutic promise and its side effect profile continues to drive cannabinoid research today. The pivot toward endocannabinoid system modulators and whole-plant medicines has since yielded approved medications like nabiximols (Sativex) and prescription CBD (Epidiolex).
What This Study Doesn't Tell Us
As a narrative review, it did not use systematic search methods or meta-analytic techniques. The evidence base in 2007 included many small studies and animal models with limited human clinical trial data.
Questions This Raises
- ?What specific compounds in whole cannabis extract contribute to therapeutic effects beyond THC alone?
- ?Can endocannabinoid system modulators achieve therapeutic benefits without THC's psychoactive effects?
Trust & Context
- Key Stat:
- Whole cannabis extract outperformed isolated THC in some therapeutic comparisons
- Evidence Grade:
- This is a narrative review of the literature as of 2007, providing a broad but non-systematic overview of THC pharmacology.
- Study Age:
- Published in 2007. Significant advances have occurred since, including FDA approval of CBD-based Epidiolex (2018) and expanded clinical trials of cannabinoid medicines.
- Original Title:
- On the pharmacological properties of Delta9-tetrahydrocannabinol (THC).
- Published In:
- Chemistry & biodiversity, 4(8), 1664-77 (2007)
- Authors:
- Costa, Barbara
- Database ID:
- RTHC-00270
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is the "entourage effect"?
The idea that whole cannabis extracts containing multiple compounds (THC, CBD, terpenes, etc.) may produce therapeutic effects that exceed what any single compound achieves alone. This review noted early evidence for this concept.
Why can't THC just be used as medicine like any other drug?
THC produces psychoactive effects (the "high"), and patients can develop tolerance (needing more for the same effect) and dependence. These issues make dosing and long-term use more complicated than with many conventional medications.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00270APA
Costa, Barbara. (2007). On the pharmacological properties of Delta9-tetrahydrocannabinol (THC).. Chemistry & biodiversity, 4(8), 1664-77.
MLA
Costa, Barbara. "On the pharmacological properties of Delta9-tetrahydrocannabinol (THC).." Chemistry & biodiversity, 2007.
RethinkTHC
RethinkTHC Research Database. "On the pharmacological properties of Delta9-tetrahydrocannab..." RTHC-00270. Retrieved from https://rethinkthc.com/research/costa-2007-on-the-pharmacological-properties
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.